These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37913735)

  • 1. SHP2 potentiates anti-PD-1 effectiveness through intervening cell pyroptosis resistance in triple-negative breast cancer.
    Chen C; Cheng Y; Lei H; Feng X; Zhang H; Qi L; Wan J; Xu H; Zhao X; Zhang Y; Yang B
    Biomed Pharmacother; 2023 Dec; 168():115797. PubMed ID: 37913735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer.
    Yan H; Luo B; Wu X; Guan F; Yu X; Zhao L; Ke X; Wu J; Yuan J
    Int J Biol Sci; 2021; 17(10):2606-2621. PubMed ID: 34326697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
    Martin E; Agazie YM
    Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer.
    Wu L; Bai S; Huang J; Cui G; Li Q; Wang J; Du X; Fu W; Li C; Wei W; Lin H; Luo ML
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
    Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
    J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing MFHAS1 Induces Pyroptosis
    Jin Y; Zhai M; Cao R; Yu H; Wu C; Liu Y
    Curr Pharm Des; 2023; 29(42):3408-3420. PubMed ID: 37936452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
    Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway.
    Yang Y; Liu PY; Bao W; Chen SJ; Wu FS; Zhu PY
    BMC Cancer; 2020 Jan; 20(1):28. PubMed ID: 31924176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
    Zhao H; Agazie YM
    BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
    Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
    Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
    Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
    Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy.
    Wang X; Li H; Li W; Xie J; Wang F; Peng X; Song Y; Tan G
    Cell Biol Toxicol; 2020 Oct; 36(5):437-457. PubMed ID: 31993881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis.
    Wu Z; Wu H; Wang Z; Li H; Gu H; Xia E; Yan C; Dai Y; Liu C; Wang X; Lv L; Bao J; Wang O; Dai X
    Phytomedicine; 2023 Jun; 114():154769. PubMed ID: 36940580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
    Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
    J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 18. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
    Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
    PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
    Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
    Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.